Teijin Pharma’s Gout Drug Obtains Marketing Authorization In Europe
This article was originally published in PharmAsia News
Executive Summary
Teijin Pharma announced May 7 that its licensee for the EU, Paris-based Ipsen, was granted marketing authorization by the European Commission for TMX-67 (febuxostat) for the treatment of chronic hyperuricemia in gout. Ipsen submitted the application to the EMEA in August 2006 and received a positive opinion this past February. TMX-67 is a non-purine selective inhibitor of xanthine oxidase with a different structure than allopurinol. Ispen will market the drug under the name of Adenuric. (Click here for more - Japanese language)
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.